Biotech

Matt's Take Matthew Herper

STAT Plus: How controversial was the decision by FDA’s Peter Marks to approve Sarepta’s gene therapy? Check its footnotes

Biotech Adam Feuerstein

STAT Plus: The biotech scorecard for the third quarter: 19 stock-moving events to watch

Biotech Jonathan Wosen

STAT Plus: Cassava Sciences collaborator charged with defrauding NIH in grants supporting its Alzheimer’s drug

The Readout Meghana Keshavan

STAT Plus: Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?

Biotech Jason Mast

STAT Plus: FDA rejects Rocket Pharmaceuticals’ gene therapy for ultra-rare condition, another setback for field

In the Lab Jason Mast

STAT Plus: Trying to outrun her prion disease, researcher creates powerful epigenetic editor in mice

The Readout Elaine Chen

STAT Plus: Exclusive: European VC Forbion hires Dyne CEO, expands in US

Biotech John Wilkerson

STAT Plus: FDA issues long-awaited draft guidance for enrolling more people of color in clinical trials

The Readout Elaine Chen

STAT Plus: Intellia says its CRISPR-based therapy can be redosed

Exclusive Allison DeAngelis

STAT Plus: Biotech accelerator Curie.Bio extends its reach with new $380 million fund

Health tech Brittany Trang

STAT Plus: Q&A: How Flagship’s Cellarity is using AI to understand cell disease biology before treating it

The Readout Elaine Chen

STAT Plus: One firm, two conflicting takes on Alnylam’s HELIOS-B 

Biotech Jason Mast

STAT Plus: Former Moderna executive launches genome editing company

Health tech Lizzy Lawrence and Elaine Chen

STAT Plus: Experts split on whether Eli Lilly’s Zepbound will hamper CPAP sales

Biotech Matthew Herper

STAT Plus: Grail, aiming to market a blood test for cancer, faces host of challenges as it debuts on Nasdaq

The Readout Meghana Keshavan

STAT Plus: The findings from Alnylam’s highly anticipated readout  

Biotech Elaine Chen

STAT Plus: Alnylam reports positive results for heart drug in pivotal study, likely clearing path to approval

Biotech Adam Feuerstein

STAT Plus: What the Sarepta decision means for Duchenne patients, the company, and the FDA

The Readout Meghana Keshavan

STAT Plus: Can JAK inhibitors bolster checkpoint inhibitors? 

Biotech Jason Mast and Matthew Herper

STAT Plus: Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Ginkgo Bioworks lays off 158 employees, with more to come

Biotech Jason Mast

STAT Plus: FDA approves Sarepta’s Duchenne gene therapy for nearly all patients

The Readout LOUD Allison DeAngelis and Adam Feuerstein

STAT Plus: Listen: Fauci’s memoir, Alnylam’s tenuous trial, and a mid-year review

Biotech Elaine Chen

STAT Plus: Zealand’s amylin-targeting drug shows early potential in obesity

Biotech Jason Mast

STAT Plus: Gilead’s twice-yearly antiviral protected women from HIV infection in large trial

The Readout Elaine Chen

STAT Plus: Lilly takes more actions against unapproved versions of Mounjaro

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: A primer on HELIOS-B, an enormous stock-moving event for Alnylam Pharmaceuticals

The Readout Adam Feuerstein

STAT Plus: A biotech’s binary bet ends badly

Biotech Matthew Herper

STAT Plus: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease